Hansen Medical Secures $30 Million in Series C Financing Led by Vanguard Ventures.

MOUNTAIN VIEW, Calif. -- Hansen Medical, Inc., a developer of robotic technology for accurate control of catheter movement in three dimensions (3D) during therapeutic cardiac procedures, announced today it has completed the sale of $30 million of series C preferred stock. This brings the total equity investment in the company to over $58 million. Vanguard Ventures, a leading, early-stage venture capital firm, led the round with participation from existing investors including Prospect Venture Partners, Skyline Venture Partners, Thomas Weisel Healthcare Venture Partners, De Novo Ventures and Sapient Capital.

The capital raised will be used to fund the company's ongoing research and development efforts, as well as the launch and commercialization of the Hansen Robotic Catheter System (RCS)(1) into the electrophysiology market in 2006. The Hansen Medical technology includes a robotic catheter manipulator which responds instinctively to physicians' commands input to a workstation, and is designed to allow physicians to place ablation catheters in hard-to-reach anatomical locations within the heart. The technology is also designed to allow physicians to maintain stability during treatment of complex cardiac arrhythmias, such as atrial fibrillation, a major cause of embolic stroke and severe long-term disability.

"Strong momentum exists in the catheter guidance market place and Hansen Medical is well positioned to become the leader in this space based on its ability to enhance both the speed and safety of catheter-based procedures," said Thomas C. McConnell, general partner of Vanguard Ventures. "The Hansen Medical technology is designed to offer increased control over catheter placement inside the heart, and should allow physicians to perform complex procedures less invasively, with better outcomes."

Hansen Medical has a portfolio of more than 50 patents and patent applications principally related to minimally invasive robotic intervention. Recently, the company entered into a cross license agreement with Intuitive Surgical, Inc., giving it the right to use technologies covered under Intuitive Surgical's issued and pending patents in the field of intravascular approaches that enable the diagnosis or treatment of cardiovascular, neurovascular and peripheral vascular diseases.

"We are very excited to receive this round of funding led by Vanguard Ventures and appreciative of the continued support from our existing investors," said Frederic Moll, M.D., founder and chief executive officer of Hansen Medical. "This new funding will help us continue to aggressively build our business and, once cleared for sale by the FDA, allow us to launch this exciting new product. Additionally, the funding will help us continue to explore the vast opportunities for this technology that extend well beyond our initial applications in treating cardiac arrhythmias."

About Hansen Medical

Hansen Medical, based in Mountain View, Calif., was founded in 2002 to develop technology for the accurate and efficient control of catheter movement in 3D spaces during therapeutic procedures. The Hansen RCS is compatible with fluoroscopy, ultrasound, 3D surface map and patient electrocardiogram data. Additionally, the workstation is transportable, can be easily moved among catheter lab suites and does not require construction of a specialized room. Hansen Medical anticipates its proprietary system, if cleared for sale, will enhance the speed and safety of catheter-based therapeutic procedures by offering physicians control over catheter placement, not achievable with existing interventional techniques. Additional information can be found at www.hansenmedical.com.

(1) The Hansen RCS requires regulatory clearance and is not yet commercially available.